Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Tixagevimab/cilgavimab  COVID-19 treatment studies for Tixagev../c..  C19 studies: Tixagev../c..  Tixagev../c..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ FDA (DB RCT) 40% 0.60 [0.35-1.03] symp. case 28/749 23/372 Improvement, RR [CI] Treatment Control Levin (DB RCT) 86% 0.14 [0.01-2.98] death 0/3,441 2/1,731 Tau​2 = 0.00, I​2 = 0.0%, p = 0.042 Prophylaxis 42% 0.58 [0.34-0.98] 28/4,190 25/2,103 42% improvement All studies 42% 0.58 [0.34-0.98] 28/4,190 25/2,103 42% improvement 2 tixagevimab/cilgavimab COVID-19 studies c19early.com/tc May 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.042 Effect extraction pre-specified(most serious outcome, see appendix) Favors tixagevimab/ci.. Favors control
Tixagevimab/cilgavimab COVID-19 studies. Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape. Recent:
Levin.
Tixagevimab/cilgavimab has been officially adopted for early treatment in 2 countries. Submit updates/corrections.
May 20
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis)
meta-analysis
Tixagevimab/cilgavimab for COVID-19: real-time meta analysis of 2 studies
Details   • Meta analysis using the most serious outcome reported shows 42% [2‑66%] improvement. Results are better for peer-reviewed studies. • One study shows statistically significant improvement in isolation (not for the most serious..
Apr 20
PrEPPEP Levin et al., New England Journal of Medicine, doi:10.1056/NEJMoa2116620
death, ↓85.7%, p=0.11
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Details   PrEP RCT with 3,441 tixagevimab/cilgavimab patients and 1,731 control patients, showing lower risk of symptomatic cases with treatment.
Dec 8
2021
PrEPPEP FDA (Preprint)
symp. case, ↓39.5%, p=0.07
Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab)
Details   PEP RCT with 749 tixagevimab/cilgavimab patients and 372 control patients, showing lower risk of symptomatic cases with treatment, without statistical significance. STORM CHASER. NCT04625972.
Dec 8
2021
PrEPPEP Levin et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab466.1646 (Preprint)
death, ↓85.7%, p=0.11
PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
Details   PrEP RCT with 3,441 tixagevimab/cilgavimab patients and 1,731 control patients, showing lower risk of symptomatic cases with treatment. Followup data is from . PROVENT. NCT04625725.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit